FI47102C - Menetelmä (3,5-diamino-6-halogeenipyratsinoyyli)guandiinien valmistami seksi, joilla on diureettiset ja/tai salureettiset ominaisuudet. - Google Patents

Menetelmä (3,5-diamino-6-halogeenipyratsinoyyli)guandiinien valmistami seksi, joilla on diureettiset ja/tai salureettiset ominaisuudet.

Info

Publication number
FI47102C
FI47102C FI640911A FI91164A FI47102C FI 47102 C FI47102 C FI 47102C FI 640911 A FI640911 A FI 640911A FI 91164 A FI91164 A FI 91164A FI 47102 C FI47102 C FI 47102C
Authority
FI
Finland
Prior art keywords
halopyrazinoyl
diners
diuretic
guanine
diamino
Prior art date
Application number
FI640911A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI47102B (en:Method
Inventor
Gragoe
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of FI47102B publication Critical patent/FI47102B/fi
Application granted granted Critical
Publication of FI47102C publication Critical patent/FI47102C/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
FI640911A 1962-10-30 1964-04-27 Menetelmä (3,5-diamino-6-halogeenipyratsinoyyli)guandiinien valmistami seksi, joilla on diureettiset ja/tai salureettiset ominaisuudet. FI47102C (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23423062A 1962-10-30 1962-10-30
US313315A US3313813A (en) 1962-10-30 1963-10-07 (3-amino-5, 6-disubstituted-pyrazinoyl) guanidines

Publications (2)

Publication Number Publication Date
FI47102B FI47102B (en:Method) 1973-05-31
FI47102C true FI47102C (fi) 1973-09-10

Family

ID=26927694

Family Applications (1)

Application Number Title Priority Date Filing Date
FI640911A FI47102C (fi) 1962-10-30 1964-04-27 Menetelmä (3,5-diamino-6-halogeenipyratsinoyyli)guandiinien valmistami seksi, joilla on diureettiset ja/tai salureettiset ominaisuudet.

Country Status (13)

Country Link
US (1) US3313813A (en:Method)
BE (1) BE639386A (en:Method)
BR (1) BR6354164D0 (en:Method)
CH (1) CH465617A (en:Method)
CY (1) CY440A (en:Method)
DE (2) DE1470053A1 (en:Method)
DK (4) DK114978B (en:Method)
FI (1) FI47102C (en:Method)
FR (1) FR1563612A (en:Method)
GB (1) GB1066855A (en:Method)
MY (1) MY6900026A (en:Method)
NL (2) NL142413B (en:Method)
SE (1) SE321230B (en:Method)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6409714A (en:Method) * 1962-10-30 1965-10-01
US3472848A (en) * 1966-11-17 1969-10-14 Merck & Co Inc 3-hydroxy and 3-mercapto-pyrazinoyl-guanidines,corresponding ethers and thioethers and processes for their preparation
US3948895A (en) * 1971-09-28 1976-04-06 E. I. Du Pont De Nemours And Company Synthesis of 3,5-diaminopyrazinoic acid from 3,5-diamino-2,6-dicyanopyrazine and intermediates
US4085211A (en) * 1975-12-15 1978-04-18 Merck & Co., Inc. Pyrazinecarboxamides and processes for preparing same
US4087526A (en) * 1976-07-23 1978-05-02 Merck & Co., Inc. (3-Amino-5-substituted-6-fluoropyrazinoyl or pyrazamido)-guanidines and their derivatives bearing substituents on the guanidino nitrogens
US4208413A (en) * 1977-03-04 1980-06-17 Merck & Co., Inc. N-Pyrazinecarbonyl-N'-alkoxycarbonyl and N',N"-bis(alkoxycarbonyl)guanidines and processes for preparing same
US4108859A (en) * 1977-06-06 1978-08-22 The Dow Chemical Company Microbicidal (pyridinylamino) alkyl guanidines
US4140776A (en) * 1977-09-16 1979-02-20 Merck & Co., Inc. N-pyrazinecarbonyl-N'-acylguanidines
US4190655A (en) * 1978-08-28 1980-02-26 Merck & Co., Inc. Amiloride citrate
EP0009054A1 (en) * 1978-09-19 1980-04-02 Merck & Co. Inc. N-Pyrazinecarbonyl-N'-substituted-sulfamoyl-guanidine and processes for preparing same
US4246406A (en) * 1979-03-27 1981-01-20 Merck & Co., Inc. Heterocyclic substituted pyrazinoylguanidines
US4224447A (en) * 1979-03-27 1980-09-23 Merck & Co., Inc. Novel pyrazinecarboxamides and processes for preparing same
US4309540A (en) * 1980-05-19 1982-01-05 Merck & Co., Inc. Substituted pyrazinyl-1,2,4-oxadiazoles
US4362724A (en) * 1980-05-19 1982-12-07 Merck & Co., Inc. Method of treating edema and hypertension and pharmaceutical composition therefor in which the active ingredient comprises a novel substituted pyrazinyl-1,2,4-oxadiazole and a kaliuretic diuretic
US4454132A (en) * 1981-03-16 1984-06-12 Merck & Co., Inc. Pharmaceutical compositions of novel substituted pyrazinyl-1,2,4-oxadiazoles useful in the treatment of edema and hypertension
US4510322A (en) * 1981-07-13 1985-04-09 Merck & Co., Inc. Indacrinone having enhanced uricosuric
US4952582A (en) * 1982-01-04 1990-08-28 Beyer Jr Karl H Pyrazinoylguanidine and derivatives thereof having few polar substituents and being useful as hyperuretic agents
US4663322A (en) * 1982-01-04 1987-05-05 Beyer Jr Karl H Antihypertensive hyperuretic and saluretic agent combinations
DE3312516A1 (de) * 1983-04-07 1984-10-11 Brigitte Dr. 7400 Tübingen Pfeiffer Kernsubstituierte phenylalkylenguanidinderivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
US4604394A (en) * 1984-10-01 1986-08-05 Merck & Co., Inc. Antiarrhythmic compositions and method
DE3925847A1 (de) * 1989-08-04 1991-02-07 Huels Chemische Werke Ag Verfahren zur herstellung von 3-aminopyrazin-2-carbonsaeuremethylester
US5304125A (en) * 1990-10-05 1994-04-19 The University Of North Carolina Apparatus for administering solid particulate aerosols to the lungs
KR930701992A (ko) * 1990-10-05 1993-09-08 웨인 알.조운즈 환자의 폐에 잔존하는 점액 분비물의 제거 방법
TW213903B (en:Method) * 1991-08-16 1993-10-01 Boehringer Ingelheim Kg
US6169107B1 (en) 1993-04-28 2001-01-02 Sumitomo Pharmaceutical Co., Ltd. Indoloylguanidine derivatives
DE4337609A1 (de) * 1993-11-04 1995-05-11 Boehringer Ingelheim Kg Neue Pyrazincarboxamidderivate, ihre Herstellung und ihre Verwendung in Arzneimitteln
US5656256A (en) * 1994-12-14 1997-08-12 The University Of North Carolina At Chapel Hill Methods of treating lung disease by an aerosol containing benzamil or phenamil
TW372967B (en) * 1994-12-27 1999-11-01 Kanebo Ltd 1,4 benzoxazine derivative, pharmaceutical composition containing the same and use thereof
US5635160A (en) 1995-06-07 1997-06-03 The University Of North Carolina At Chapel Hill Dinucleotides useful for the treatment of cystic fibrosis and for hydrating mucus secretions
US5628984A (en) * 1995-07-31 1997-05-13 University Of North Carolina At Chapel Hill Method of detecting lung disease
US5801177A (en) * 1995-12-14 1998-09-01 Beyer, Jr.; Karl H. Method for controlling and/or lowering serum glucose and fatty acid concentrations and hypertensive blood pressure in non-insulin-dependent diabetic patients
US5877217A (en) * 1995-12-26 1999-03-02 Alteon Inc. N-acylaminoalkyl-hydrazinecarboximidamides
DE69828892D1 (de) * 1997-08-29 2005-03-10 Univ North Carolina Verwendung von uridin-5'-diphosphat und analoge zur behandlung von lungenerkrankungen
WO2000023023A1 (en) * 1998-10-20 2000-04-27 The University Of North Carolina At Chapel Hill Methods of hydrating mucosal surfaces
CA2360687A1 (en) * 1999-01-29 2000-08-03 Karl H. Beyer, Jr. (Deceased) Composition and method for treating diabetes
PT1196396E (pt) * 1999-07-19 2008-05-14 Univ North Carolina Compostos farmacologicamente activos com dois princípios activos covalentemente ligados (bloqueador dos canais do sódio/agonista do receptor p2y2) para o tratamento de superfícies mucosas
MXPA03004463A (es) 2000-11-21 2003-08-19 Sankyo Co Composiciones medicas.
US6858615B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenyl guanidine sodium channel blockers
US6858614B2 (en) * 2002-02-19 2005-02-22 Parion Sciences, Inc. Phenolic guanidine sodium channel blockers
WO2003093297A2 (en) * 2002-05-03 2003-11-13 Exelixis, Inc. Protein kinase modulators and methods of use
US7704995B2 (en) * 2002-05-03 2010-04-27 Exelixis, Inc. Protein kinase modulators and methods of use
MXPA05001958A (es) 2002-08-19 2005-04-28 Pfizer Prod Inc Terapia de combinacion para enfermedades hiperproliferativas.
US6903105B2 (en) * 2003-02-19 2005-06-07 Parion Sciences, Inc. Sodium channel blockers
AU2004248859C1 (en) * 2003-06-26 2011-11-24 Biotron Limited Antiviral acylguanidine compounds and methods
EP2617709B8 (en) * 2003-06-26 2022-12-21 Biotron Limited Guanidine derivatives as antiviral agents
US7326706B2 (en) * 2003-08-15 2008-02-05 Bristol-Myers Squibb Company Pyrazine modulators of cannabinoid receptors
EP1670475A4 (en) * 2003-08-18 2009-04-15 Parion Sciences Inc ALAPHATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS
KR20060060027A (ko) * 2003-08-18 2006-06-02 패리온 사이언스 인코퍼레이티드 캡핑된 피라지노일구아니딘 나트륨 채널 차단제
US20050090505A1 (en) * 2003-08-18 2005-04-28 Johnson Michael R. Methods of reducing risk of infection from pathogens
US20090253714A1 (en) * 2003-08-20 2009-10-08 Johnson Michael R Methods of reducing risk of infection from pathogens
US7745442B2 (en) 2003-08-20 2010-06-29 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens
US20070099968A1 (en) * 2004-06-26 2007-05-03 Biotron Limited Antiviral compounds and methods
US20070021439A1 (en) * 2005-07-25 2007-01-25 Parion Sciences, Inc. Methods of reducing risk of infection from pathogens with soluble amide and ester pyrazinoylguanidine sodium channel blockers
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
CA2630920A1 (en) * 2005-11-22 2007-05-31 University Of South Florida Inhibition of cell proliferation
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
ATE547394T1 (de) 2006-12-01 2012-03-15 Bristol Myers Squibb Co N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
AU2008310734B2 (en) 2007-10-10 2014-06-05 Parion Sciences, Inc. Delivering osmolytes by nasal cannula
AR070527A1 (es) 2008-02-26 2010-04-14 Johnson Michael R Bloqueadores poliaromaticos del canal de sodio
DE102008053024B4 (de) 2008-10-24 2015-04-30 RUHR-UNIVERSITäT BOCHUM Verwendung von Amilorid-Derivaten zur Bekämpfung von Insekten und Milben
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
US8945605B2 (en) 2011-06-07 2015-02-03 Parion Sciences, Inc. Aerosol delivery systems, compositions and methods
DK2723176T3 (en) 2011-06-27 2017-07-31 Parion Sciences Inc CHEMICAL AND METABOLIC STABLE DIPEPTIDE WITH POTENT SODIUM CHANNEL BLOCK ACTIVITY
AR086745A1 (es) 2011-06-27 2014-01-22 Parion Sciences Inc 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil)carbamimidoil)pirazina-2-carboxamida
ES2675588T3 (es) 2012-05-29 2018-07-11 Parion Sciences, Inc. Dendrímero como aminoamidas que posee actividad de bloqueador de canal de sodio para el tratamiento del ojo seco y otras enfermedades mucosas
HUE032891T2 (hu) 2012-12-17 2017-11-28 Parion Sciences Inc Klórpirazin-karboxamid-származékok nem kielégítõ nyálkahártya-hidratáció által elõsegített megbetegedések kezelésére
CN104995178B (zh) 2012-12-17 2018-06-26 帕里昂科学公司 3，5-二氨基-6-氯-n-(n-(4-苯基丁基)甲脒基)吡嗪-2-甲酰胺化合物
CN105143203A (zh) 2013-04-17 2015-12-09 辉瑞大药厂 用于治疗心血管疾病的n-哌啶-3-基苯甲酰胺衍生物
JP6449870B2 (ja) * 2013-07-08 2019-01-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肺および気道の疾患を処置するための上皮性ナトリウムチャネルの阻害剤としてのアミロライド型化合物
US9102633B2 (en) 2013-12-13 2015-08-11 Parion Sciences, Inc. Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compounds
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
CA3030949A1 (en) * 2016-07-29 2018-02-01 Toray Industries, Inc. Guanidine derivative and medical use thereof
JOP20210193A1 (ar) 2019-01-18 2023-01-30 Astrazeneca Ab مثبطات pcsk9 وطرق استخدامها

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL299929A (en:Method) * 1962-10-30

Also Published As

Publication number Publication date
FI47102B (en:Method) 1973-05-31
CY440A (en) 1968-05-18
US3313813A (en) 1967-04-11
BE639386A (en:Method)
DE1470053A1 (de) 1969-06-26
NL142413B (nl) 1974-06-17
CH465617A (de) 1968-11-30
BR6354164D0 (pt) 1973-09-18
DE1795438C2 (de) 1974-04-11
DE1795438B1 (de) 1973-09-06
DK116943B (da) 1970-03-02
DK114557B (da) 1969-07-14
NL299931A (en:Method)
DK114978B (da) 1969-08-25
DK115403B (da) 1969-10-06
MY6900026A (en) 1969-12-31
SE321230B (en:Method) 1970-03-02
GB1066855A (en) 1967-04-26
FR1563612A (en:Method) 1969-04-18

Similar Documents

Publication Publication Date Title
FI47102C (fi) Menetelmä (3,5-diamino-6-halogeenipyratsinoyyli)guandiinien valmistami seksi, joilla on diureettiset ja/tai salureettiset ominaisuudet.
DK143227C (da) Analogifremgangsmaade til fremstilling af substituerede 2,2'-methylendiphenoler eller farmakologisk acceptable salte deraf
CH508584A (de) Verfahren zur Herstellung von neuen substituierten 1-Amino-2-hydroxy-3-(2'-cyclopentyl- bzw. (2'-( 2-cyclopentenyl)-phenoxy)-propanen
FI56531B (fi) Foerfarande foer framstaellning av isotiocyanobenstiazoler med antelmintisk och mikrobicid verkan
DK128805B (da) Rygevare eller bestanddel deraf.
FI40032C (fi) Förfarande och anordning för framställning av planglas i bandform
FI53310C (fi) Foerfarande foer framstaellning av analgetiskt och/eller morfinantagonistiskt verkande 9,9-disubstituerade 6,7-bensomorfaner samt dessas optiska enantiomerer och terapeutiskt godtagbara syraadditionssalter
DK114131B (da) Fremgangsmåde til fremstilling af 1β-hydroxy-5-oxo-4-(2'-carboxyethyl)-7αβ-methyl-3aα,4β,5,6,7,7a-hexahydroindan eller acylderivater deraf.
FI55343C (fi) Foerfarande foer framstaellning av nya, blodtryckssaenkande 3-hydrazinopyrido(4,3-c)pyridazinderivat
SE384501B (sv) Forfarande for framstellning av d,d'-2,2'-(etylendiimino)-di-1-butanol-dihydroklorid
FR1377073A (fr) Système d'atterrissage pour avions
FI46376C (fi) Menetelmä steroidi-(17alfa,16alfa-d)-oksatsolidiinien ja steroidi-(17a lfa,16alfa-d)-oksatsolidiinioksatsiinien valmistamiseksi
FI44913C (fi) Menetelmä uusien substituoitujen fenyyliamino-1,3-diatsasyklopenteenien-(2) valmistamiseksi, joilla on verenpainetta alentava ja rauhoittava vaikutus
DK115916B (da) Fremgangsmåde til fremstilling af 1-(2'-desoxy-D-ribofuranosyl)-5-fluor-cytosiner eller 4-N-p-toluoylderivater deraf.
DK114487B (da) Fremgangsmåde til fremstilling af 2,4-diaminopyrido-[2,3,-d]-pyrimidiner eller syreadditionssalte heraf.
DK107742C (da) Fremgangsmåde til fremstilling af 1β-hydroxy-5-oxo-4-(2'-carboxyethyl)-7aβ-methyl-5,6,7,7a-tetrahydroindan eller estere deraf.
BE791949A (fr) Derives d'insuline, leur preparation et leur utilisation
FR1333200A (fr) Perfectionnements apportés à la construction de fuselages d'aérodynes
FI47108C (fi) Menetelmä (3-aminopyratsiiniamido)guanidiinien valmistamiseksi, joilla on diureettiset ja/tai salureettiset ominaisuudet.
FI43995C (fi) Förfarande för framställning av 3,3'-di-2-imidazolin-2-yl-karbanilid och syraadditionssalter därav
SU604941A1 (ru) Металлический лестничный марш
FR1258619A (fr) Aile d'avion
CH419118A (de) Herstellung von in 17a-Stellung substituierten 3-Niederalkoxy-1,3,5(10)-östratrien-17B-olen
CH552406A (fr) Emulsion, procede de preparation de l'emulsion, et utilisation de celle-ci.
BE790284A (fr) Preparation de 2,4,6-tris-(hydroxybenzylthio) triazines